Arrowhead Pharmaceuticals share price logo

Arrowhead Pharmaceuticals

NASDAQ: ARWR

Large Cap

$87.11

-0.36

(-0.41%)

as on

Arrowhead Pharmaceuticals Stock Performance

as on August 22, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $85.94
    $88.46
    downward going graph

    1.34%

    Downside

    1.55%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $19.42
    $95.49
    downward going graph

    77.71%

    Downside

    9.62%

    Upside

    downward going graph

Arrowhead Pharmaceuticals share price movements today

Previous Close
$87.47
Open
$87.66
Volume
742.0K
Market Cap
$12.2B
Day's Low - High
$85.94 - $88.46
52 Week Low - High
$19.42 - $95.49

Arrowhead Pharmaceuticals Historical Returns

1 Month Return
+ 16.61 %
3 Month Return
+ 13 %
1 Year Return
+ 322.43 %
3 Year Return
+ 198.55 %
5 Year Return
+ 42.81 %

Arrowhead Pharmaceuticals Stock Fundamentals & Key Indicators

Check Arrowhead Pharmaceuticals market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$12.2B

EPS (TTM)

-3.5055

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.10%

PE Ratio (TTM)

0

PEG Ratio

-1.32

EBITDA

-200.6M

Revenue (TTM)

669.5M

Profit Margin

-47.79%

Return On Equity TTM

-55.21%

Arrowhead Pharmaceuticals vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Arrowhead Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$12.2B42.81%NA-47.79%NA
BUY$43.7B669.3%NA0.00%NA
BUY$128.2B154.86%29.8286.04%NA
BUY$25.3B-84.24%-7.98-12.57%NA
BUY$82.7B24.1%19.2484.86%0.44999999999999996%

Stock Returns calculator for Arrowhead Pharmaceuticals Stock including INR - Dollar returns

The Arrowhead Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Arrowhead Pharmaceuticals investment value today

Current value as on today

₹4,65,470

Returns

₹3,65,470

(+365.47%)

Returns from Arrowhead Pharmaceuticals Stock

₹3,24,720 (+324.72%)

Dollar Impact

₹40,750 (+40.75%)

Analyst Recommendation on Arrowhead Pharmaceuticals Stock

Based on 10 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 10 analysts, 100% of analysts recommend a 'BUY' rating for Arrowhead Pharmaceuticals. Average target price of $110.18

Arrowhead Pharmaceuticals Share Price Target

Get share price movements and forecasts by analysts on Arrowhead Pharmaceuticals.

What analysts predicted

20.94%UPSIDE

Target Price

$110.18

Current Price

$87.11

Analyzed by

10 Analysts

Target

$110.18

Arrowhead Pharmaceuticals target price $110.18, a slight upside of 20.94% compared to current price of $87.11. According to 10 analysts rating.

Indian Investors' Interest in Arrowhead Pharmaceuticals Stock

Search interest for Arrowhead Pharmaceuticals Stock has increased by 197% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:197% versus previous 30 day period

Arrowhead Pharmaceuticals Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
-
23
2
542
27
256
264
73
75
Gross Profit
-4
-4
-5
2
542
27
256
264
73
75
Operating Income
-126
-176
-162
-161
381
-165
44
40
-141
-170
EBITDA
-115
-164
-153
-148
397
-148
64
57
-107
-154
Interest Expense
7
5
14
21
21
24
21
22
23
24
Depreciation
4
4
5
5
6
6
6
6
6
6
Income Before Tax
-126
-173
-172
-175
369
-179
36
28
-137
-178
Income Tax Expense
-1
-3
0
0
1
0
20
0
0
0
Net Income
-125
-170
-170
-173
370
-175
-23
30
-132
-194
Net Profit Margin
0.00%
0.00%
-722.95%
-6923.40%
68.26%
-631.11%
-9.26%
11.67%
-180.01%
-258.17%

Arrowhead Pharmaceuticals Annual Profit & Loss

All numbers in Millions USD

Sep 2016
Sep 2017
Sep 2018
Sep 2019
Sep 2020
Sep 2021
Sep 2022
Sep 2023
Sep 2024
Sep 2025
Total Revenue
0
31
16
168
87
138
243
240
3
829
Gross Profit
0
31
16
168
87
138
243
228
-15
829
Operating Income
-81
-36
-55
61
-93
-149
-178
-205
-601
98
EBITDA
-76
-32
-51
65
-87
-132
-168
-175
-561
164
Interest Expense
265
415
1,048
6,957
9,190
6
5
18
32
89
Depreciation
-
4
4
4
5
8
10
12
18
23
Income Before Tax
-81
-34
-54
68
-84
-140
-172
-206
-612
51
Income Tax Expense
0
0
0
0
0
0
3
2
-2
21
Net Income
-81
-34
-54
67
-84
-140
-176
-205
-599
-1
Net Profit Margin
-51614.63%
-109.46%
-337.32%
40.27%
-96.09%
-101.85%
-72.56%
-85.27%
-16882.37%
-0.20%

Arrowhead Pharmaceuticals Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-173
-173
-175
367
-178
16
28
-132
-183
Operating Cash Flow
-115
-137
-146
460
-154
20
13
84
-177
Investing Cash Flow
6
-222
76
-420
141
72
-23
-894
43
Financing Cash Flow
50
389
20
92
-42
3
-14
795
0
Change in Cash
-58
33
-48
131
-55
96
-24
-13
-133

Arrowhead Pharmaceuticals Annual Cash Flow

All numbers in Millions USD

Sep 2017
Sep 2018
Sep 2019
Sep 2020
Sep 2021
Sep 2022
Sep 2023
Sep 2024
Sep 2025
Net Income
-34
-54
67
-84
-140
-176
-209
-609
30
Operating Cash Flow
-23
-47
173
-95
171
-136
-153
-462
179
Investing Cash Flow
-48
-7
-47
-240
-141
-5
-96
-420
-129
Financing Cash Flow
12
59
66
257
11
65
253
870
74
Change in Cash
-60
5
191
-78
40
-76
2
-8
123

Mutual Funds that own Arrowhead Pharmaceuticals Stock

Check out the Mutual Funds with significant holdings in Arrowhead Pharmaceuticals.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
7.484278%
10571878
Fidelity Mt. Vernon Street Trust
2.222869%
3139902
Fidelity Salem Street Trust
1.256309%
1774594
Fidelity Concord Street Trust
0.984621%
1390822
ALGER INSTITUTIONAL FUNDS
0.834327%
1178525

Global Institutional Holdings in Arrowhead Pharmaceuticals

Funds
Holdings
iShares
9.18%
Vanguard
8.38%
SPDR
2.83%
David Gerald Greenspan
1.79%
Invesco
1.59%

Arrowhead Pharmaceuticals News & Key Events

  • img

    Today's Timeline - 21 April

    Tue, 07:33 PM

    -

    Morgan Stanley upgrades Arrowhead to Overweight, raising price target to $100, citing strong momentum ahead of Phase 3 data.

Insights on Arrowhead Pharmaceuticals

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, ARWR stock has moved up by 308.4%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 73.73M → 75.25M (in $), with an average increase of 2.0% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 466.0% return, outperforming this stock by 157.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 586.8% return, outperforming this stock by 379.9%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, 30.81M → -194.27M (in $), with an average decrease of 288.6% per quarter

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
OrganisationArrowhead Pharmaceuticals
Headquarters177 East Colorado Boulevard, Pasadena, CA, United States, 91105
IndustryBiotechnology
CEODr. Christopher R. Anzalone Ph.D.
E-voting on sharesClick here to vote

Key Management of Arrowhead Pharmaceuticals

Name

Title

Dr. Mark Seefeld

Head of Toxicology & VP

Dr. Christopher R. Anzalone Ph.D.

Chairman, CEO & President

Mr. Daniel J. Apel

Chief Financial Officer

Mr. Patrick O'Brien J.D., PharmD

COO & Secretary

Dr. James C. Hamilton M.D., MBA

Chief Medical Officer and Head of R&D

Dr. Bruce D. Given M.D.

Chief Medical Scientist

Dr. Mark M. Davis Ph.D.

Founder and Founder & Director of Insert Therapeutics Inc & Calando

Dr. Tao Pei Ph.D.

Chief Scientific Officer

Dr. Vincent Anzalone CFA

Head of Investor Relations & VP

Mr. Howard Lovy

Director of Communications

FAQs

What is Arrowhead Pharmaceuticals share price today?

Arrowhead Pharmaceuticals share price today is $87.11 as on at the close of the market. Arrowhead Pharmaceuticals share today touched a day high of $88.46 and a low of $85.94.

What is the 52 week high and 52 week low for Arrowhead Pharmaceuticals share?

Arrowhead Pharmaceuticals share touched a 52 week high of $95.49 on and a 52 week low of $19.42 on . Arrowhead Pharmaceuticals stock price today i.e. is closed at $87.11,which is 8.78% down from its 52 week high and 348.56% up from its 52 week low.

What is Arrowhead Pharmaceuticals's market capitalisation today?

Arrowhead Pharmaceuticals market capitalisation is $0.01T as on .

How to invest in Arrowhead Pharmaceuticals Stock (ARWR) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Arrowhead Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Arrowhead Pharmaceuticals Shares that will get you 0.0172 shares as per Arrowhead Pharmaceuticals share price of $87.11 per share as on August 22, 2026 at 8:46 am IST.

What is the minimum amount required to buy Arrowhead Pharmaceuticals Stock (ARWR) from India?

Indian investors can start investing in Arrowhead Pharmaceuticals (ARWR) shares with as little as ₹95.71 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹957.10 in Arrowhead Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on ). Based on Arrowhead Pharmaceuticals share’s latest price of $87.11 as on August 22, 2026 at 8:46 am IST, you will get 0.1148 shares of Arrowhead Pharmaceuticals. Learn more about fractional shares .

What are the returns that Arrowhead Pharmaceuticals has given to Indian investors in the last 5 years?

Arrowhead Pharmaceuticals stock has given 42.81% share price returns and 29.17% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?